Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001.
Terese Catherine HammondRaymond C LeeBryan OronskyTony R ReidScott CaroenTiffany M JuarezJaya GillAnnie HengSantosh KesariPublished in: International medical case reports journal (2022)
Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.
Keyphrases
- small molecule
- coronavirus disease
- protein protein
- sars cov
- respiratory failure
- clinical trial
- end stage renal disease
- newly diagnosed
- anti inflammatory
- ejection fraction
- chronic kidney disease
- extracorporeal membrane oxygenation
- adipose tissue
- peritoneal dialysis
- mechanical ventilation
- prognostic factors
- intensive care unit
- study protocol
- phase ii